Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kidney transplant patients: safer rejection prevention?

NCT ID NCT06365437

Terminated Disease control Sponsor: ITB-Med LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called TCD601 (siplizumab) in 33 kidney transplant patients to see if it could safely prevent organ rejection. The drug was compared to a standard treatment (ATG). The trial was stopped early, so we have limited information, but the goal was to find a gentler option for transplant recipients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TCD601 (siplizumab)
What this could lead to
If it works, this could point toward a safer way to prevent organ rejection after kidney transplant, reducing side effects compared to current treatments.
What could go wrong
This is an early, small Phase 2 trial that was terminated, so results are limited. The drug may not prove safer or more effective than standard therapy, and risks include infection and rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitari de Bellvitge

    Barcelona, 08907, Spain

  • Innsbruck Medical University

    Innsbruck, A-6020, Austria

  • Karolinska University Hospital

    Stockholm, Huddinge, 14157, Sweden

  • Sahlgrenska University Hospital

    Gothenburg, 41345, Sweden

  • Skåne University Hospital

    Malmö, 20502, Sweden

  • University of Vienna

    Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.